SCHEMBL17455994

SCHEMBL17455994

Fc1ccc(-c2ccncc2)c(OC2CCN(Cc3ccccc3)CC2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 1/20 0.55
▸ CYP11B2 P19099 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ SCN9A Q15858 1/20 0.47
▸ DRD2 P14416 1/20 0.46
▸ HTR2A P28223 1/20 0.46
▸ HTR2C P28335 1/20 0.46
▸ HTR2B P41595 1/20 0.46
▸ SIGMAR1 Q99720 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ ROCK1 Q13464 2/20 0.44
▸ CYP46A1 Q9Y6A2 1/20 0.44
▸ ROCK2 O75116 1/20 0.44
▸ CCR2 P41597 1/20 0.44
▸ BCHE P06276 1/20 0.44
▸ ACHE P22303 1/20 0.44
▸ BACE1 P56817 1/20 0.44
▸ NMT1 P30419 1/20 0.44
▸ HRH3 Q9Y5N1 1/20 0.44
▸ SCN1A P35498 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17456041 0.94 CYP11B1 (0.53) CYP11B1CYP11B2SMN1; SMN2DRD2HTR2A
SCHEMBL17455985 0.92 SMN1; SMN2 (0.50) CYP11B1CYP11B2SMN1; SMN2SCN9AALDH1A1
SCHEMBL17455938 0.88 SMN1; SMN2 (0.57) SMN1; SMN2SCN9ASIGMAR1ROCK1ROCK2
SCHEMBL17455920 0.87 CYP46A1 (0.57) SMN1; SMN2SCN9ADRD2SIGMAR1ROCK1
SCHEMBL17455972 0.86 MCHR1 (0.50) CYP11B1CYP11B2SMN1; SMN2ROCK1ROCK2
SCHEMBL17455978 0.81 MCHR1 (0.47) CYP11B1CYP11B2SMN1; SMN2ROCK1ROCK2
SCHEMBL17455968 0.80 SMN1; SMN2 (0.53) CYP11B1CYP11B2SMN1; SMN2SCN9ADRD2
SCHEMBL17455967 0.80 SCN9A (0.51) SMN1; SMN2SCN9ADRD2SIGMAR1ALDH1A1
SCHEMBL17455988 0.78 KDM4E (0.46) CYP11B1CYP11B2SMN1; SMN2SCN9ASCN1A
SCHEMBL4125911 0.77 HRH3 (0.65) SMN1; SMN2SCN9ASIGMAR1ROCK1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 CYP11B1 88/4885CYP11B2 82/4885SMN1; SMN2 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback